GlassScriptPhysician profile
Jose A Lira
NPI 1821038985
$1,310.11
in general payments reported to CMS, 2019-2025
14 companies · $28.30 in 2025
The $28.30 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $306 · 2020: $286 · 2021: $140 · 2022: $194 · 2023: $258 · 2024: $98.64 · 2025: $28.30.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $385.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $384.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $408.25 | 2019-2024 | Opsumit, Uptravi |
| Regeneron Healthcare Solutions, INC. | $258.83 | 2022-2023 | Dupixent |
| Mylan Specialty L.P. | $152.88 | 2019 | |
| Glaxosmithkline, LLC. | $102.19 | 2020-2024 | Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.24 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $71.20 | 2019-2020 | |
| Radius Health, INC. | $52.84 | 2021 | |
| Harmony Biosciences LLC | $37.85 | 2024 | |
| Lilly USA, LLC | $33.04 | 2020-2023 | Emgality, Jardiance |
| Abbvie INC. | $28.30 | 2025 | |
| United Therapeutics Corporation | $26.30 | 2023 | Tyvaso |
| Amgen INC. | $24.64 | 2020 | |
| Novartis Pharmaceuticals Corporation | $24.39 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $15.16 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Lira listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.